A new study released to coincide with World Cancer Research Day today argues that wider access to clinical trials of new ...

Dr. Chirag Jani, a Phoebe Cancer Center hematologist and oncologist beloved by his patients and well-respected by his peers, has been named president of the Georgia Society of Clinical Oncology. Jani ...

Highlights include new safety and efficacy data of Barrigel™ rectal spacer, the first and only sculptable rectal spacer1-3 • ...

UCLA Health Jonsson Comprehensive Cancer Center researchers and physicians who specialize in treating patients with radiation ...

Phase 3 ENLIGHTED study enrollment completion expected by first quarter of 2025TEL AVIV, Israel, Sept. 27, 2024 (GLOBE ...

Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...

Camrelizumab increased the 3-year event-free survival rate vs standard of care from 77.3% to 86.9%, translating to a 44% ...

ASCO recommends osimertinib consolidation for patients with unresectable, stage III NSCLC with an EGFR exon 19 deletion or exon 21 L858R mutation who have completed chemoradiation.

The researchers noted that multiple studies have documented substantial declines in cancer incidence across multiple types of ...

The FDA has approved osimertinib (Tagrisso) for locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) ...

Researchers at Fred Hutch Cancer Center identified a substantial increase over the past decade in the proportion of patients with cancer in the U.S. who participate in pharmaceutical industry ...

Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the presentation of new data at the 66th Annual ...